Biotech firm Intellia is pushing forward with late-stage gene editing trials, even as investors remain cautious after a steep share price drop and persistent cash burn.

America’s health insurance leader faces a tough year as rising Medicare costs, management shakeups and regulatory scrutiny leave investors weighing a future rebound against lingering risks.

Exploration breakthroughs, rising receipts, and healthy cash reserves set the pace for several Australian mining firms this quarter.

A sharp drop in metal prices, US tariffs, and weak Chinese demand have weighed on Glencore, but a capital return and hopes for a copper rebound could lift fortunes later this year.

What’s going on here? A new surge in municipal bond issues across the US is pushing climate risk into the spotlight, as fresh research shows extreme weather threats are now a major factor for ...

Join the newsletter that everyone in finance secretly reads. 1M+ subscribers, 100% free. RBC Capital Markets sees J.M. Smucker's Uncrustables brand as a hidden gem, pinpointing it as a crucial driver ...

What’s going on here? Blackstone and TPG are in talks to acquire portions of H&R Real Estate Investment Trust's $7.67 billion portfolio, attracting attention from investors in the US and Canada. What ...

Join the newsletter that everyone in finance secretly reads. 1M+ subscribers, 100% free. Another day, another tariff threat. The US president turned up the trade tension dial yet again, announcing ...

The Daily Brief is a podcast that covers the top stories in finance each day – hit play to listen or follow the links below to read. Today's Stories American Copper Prices Hit A Record High On The ...

What’s going on here? Bitcoin just blasted beyond $118,000 on Friday, as traders scrambled for coins ahead of what’s expected to be a big week for crypto. What does this mean? US spot bitcoin exchange ...

Tech stocks cushion the Nikkei's fall, but tariff concerns hit Fast Retailing hard in a mixed market.

What’s going on here? Biotech stocks are climbing as Recursion Pharmaceuticals and Rallybio make big strategic moves, while Progyny excites investors with positive Q2 forecasts. Recursion ...